IP Library Granted Patent US 7,067,659
Granted Patent B2
US 7,067,659 · App. 10/829,940 · Granted Jun 27, 2006

Reactive oxygen generating enzyme inhibitor with nitric oxide bioactivity and uses thereof

Assignees: Duke University; Johns Hopkins University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,067,659
App. No.
10/829,940
Granted
Jun 27, 2006
Kind
B2
Abstract

A reactive oxygen generating enzyme inhibitor with NO donor bioactivity, e.g., nitrated allopurinol, e.g., 1,5-bis(3-nitrooxypropyyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidine-4-one is useful to treat heart failure, stable angina, ischemic disorder, ischemic reperfusion injury, atherosclerosis, sickle cell disease, diabetes, Alzheimer's disease, Parkinson's disease, ALS and asthma and to obtain proper contraction of heart, skeletal and smooth muscle. Where the disorder is heart failure, administration of the enzyme inhibitor mediates amelioration of acute coronary symptoms and/or myocardial infarction.

Claims (7)

1. An inhibitor of a reactive oxygen generating enzyme which includes a group providing NO donor bioactivity which is not a C-nitroso compound or an inhibitor of a cyclooxygenase, said inhibitor being selected from the group consisting of allopurinol, oxypurinol, pterin-6-aldehyde, and mixtures thereof, provided with a nitrate group thereon.

2. The inhibitor of claim 1 which is 1,5-bis(3-nitrooxypropyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one.

3. The inhibitor of claim 1 which is a nitrate ester.

4. A method of treating a patient with heart failure, comprising administering to that patient an amount of the inhibitor of claim 1 effective to mediate amelioration of acute coronary symptoms and/or myocardial infarction.

5. The method of claim 4 , where the inhibitor comprises 1,5-bis(3-nitrooxypropyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one.

6. A method of treating a patient with stable angina, comprising administering to that patient an amount of the inhibitor of claim 1 effective to mediate reduction or elimination of pain.

7. The method of claim 6 where the inhibitor comprises 1,5-bis(3-nitrooxypropyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one.

Assignments (5)
CONFIRMATORY LICENSE Recorded Nov 13, 2017
From: JOHNS HOPKINS UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 044428/0199 →
SECURITY AGREEMENT Recorded May 18, 2009
From: CORDEX PHARMA, INC. (F/K/A DUSKA THERAPEUTICS, INC.); DUSKA SCIENTIFIC CO.
To: PLATINUM LONG TERM GROWTH VI, LLC
Reel/Frame 022703/0553 →
CHANGE OF NAME Recorded May 18, 2009
From: DUSKA THERAPEUTICS, INC. (NOW CORDEX PHARMA, INC.)
To: PLATINUM LONG TERM GROWTH VI, LLC
Reel/Frame 023134/0138 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 8, 2005
From: HARE, JOSHUA M.
To: JOHNS HOPKINS UNIVERSITY
Reel/Frame 017193/0924 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 25, 2005
From: STAMLER, JONATHAN S.; TOONE, ERIC J.
To: DUKE UNIVERSITY
Reel/Frame 016492/0766 →
Continuity (1)
Related Publication 20050239807A1 · Oct 27, 2005